Citius Oncology Issues Warrants in Private Placement
Citius Oncology (CTOR) announced the issuance of warrants for 360,000 shares of common stock as part of a private placement, with exercise set for March 2026. The board also amended its 2024 Omnibus Stock Incentive Plan, increasing authorized shares from 15 million to 30 million. Analyst ratings for CTOR stock are mixed, with a Buy rating and a $3.00 price target, while Spark's AI Analyst rates it as Neutral, citing financial challenges and a low P/E ratio that suggests potential undervaluation.
Citius Oncology ( (CTOR) ) has provided an announcement.
On September 19, 2025, Citius Oncology, Inc. issued warrants to a financial advisor for 360,000 shares of common stock, exercisable in March 2026, as part of a private placement. Additionally, the company’s board approved an amendment to its 2024 Omnibus Stock Incentive Plan, doubling the authorized shares from 15 million to 30 million, indicating a strategic move to enhance its stock incentive offerings.
The most recent analyst rating on (CTOR) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Citius Oncology stock, see the CTOR Stock Forecast page.
Spark’s Take on CTOR Stock
According to Spark, TipRanks’ AI Analyst, CTOR is a Neutral.
Citius Oncology’s stock score reflects significant financial challenges and bearish technical indicators, offset slightly by its low P/E ratio suggesting potential undervaluation. The absence of revenue and consistent net losses underscore a high-risk profile typical of an early-stage pharmaceutical company. Technical indicators point to negative momentum, while the valuation presents a more optimistic perspective due to the low P/E ratio.
To see Spark’s full report on CTOR stock, click here.
More about Citius Oncology
Average Trading Volume: 1,716,401
Technical Sentiment Signal: Sell
Current Market Cap: $148.7M
